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Abstract: Background&Aims: c-Jun N-terminal kinase (JNK)1 and JNK2 are expressed in
hepatocytes and have overlapping and distinct functions. JNK proteins are activated,
via phosphorylation, in response to acetaminophen- or CCl4-induced liver damage; the
level of activation correlates with the degree of injury. SP600125, a JNK inhibitor, has
been reported to block acetaminophen-induced liver injury. We investigated the role of
JNK in drug-induced liver injury (DILI) in liver tissues from patients and in mice with
genetic deletion of JNK in hepatocytes. Methods: We studied liver sections from
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
patients with DILI (due to acetaminophen, phenprocoumon, non-steroidal anti-
inflammatory drugs or autoimmune hepatitis), or patients without acute liver failure
(controls), collected from a DILI Biobank in Germany. Levels of total and activated
(phosphorylated) JNK were measured by immunohistochemistry and western blotting.
Mice with hepatocyte-specific deletion of Jnk1 (Jnk1Δhepa) or combination of Jnk1 and
Jnk2 (JnkΔhepa), as well as Jnk1-floxed C57BL/6 (control) mice, were given injections
of CCl4 (to induce fibrosis) or acetaminophen (to induce toxic liver injury). We
performed gene expression microarray, and phosphoproteomic analyses to determine
mechanisms of JNK activity in hepatocytes. Results: Liver samples from DILI patients
contained more activated JNK, predominantly in nuclei of hepatocytes and in immune
cells, than healthy tissue. Administration of acetaminophen to JnkΔhepa mice
produced a greater level of liver injury than that observed in Jnk1Δhepa or control
mice, based on levels of serum markers and microscopic and histologic analysis of
liver tissues. Administration of CCl4 also induced stronger hepatic injury in JnkΔhepa
mice, based on increased inflammation, cell proliferation, and fibrosis progression,
compared to Jnk1Δhepa or control mice. Hepatocytes from JnkΔhepa mice given
acetaminophen had an increased oxidative stress response, leading to decreased
activation of AMPK, total protein AMPK levels, and pJunD and subsequent necrosis.
Administration of SP600125 before or with acetaminophen protected JnkΔhepa and
control mice from liver injury. Conclusions: In hepatocytes, JNK1 and JNK2 appear to
have combined effects in protecting mice from CCl4- and acetaminophen-induced liver
injury. It is important to study the tissue-specific functions of both proteins, rather than
just JNK1, in the onset of toxic liver injury. JNK inhibition with SP600125 shows off-
target effects.
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Re: GASTRO-D-14-01639-R2 
 
Dear Bishr, Dear Prof. Omary, 
 
Please find attached our revised manuscript GASTRO-D-14-01639-R2 “Combined 
activities of JNK1 and JNK2 protect against toxic liver injury“, which we would like you to 
resubmit to Gastroenterology. 
In order to address the concerns and suggestions of the Reviewers we have significantly 
revised the first revised version of the manuscript. Specifically, we have included data to better 
characterize JNK activation in human DILI and murine APAP-derived liver injury in vivo and to 
understand the mechanism, similar in mice and men. Furthermore, we found that mice with JNK 
deletion in hepatocytes are more sensitive to APAP-induced liver injury due to a decline in the 
protein levels of pAMPK and AMPK. However in mice with JNK deletion in hepatocytes pJNK is 
increased, which is explained by a strong infiltration of JNK-positive immune cells. These results 
strongly suggest that JNK in non-parenchymal-cells plays an essential role in APAP-induced liver 
injury. Through the helpful comments of the reviewers and the editors we clarified that SP600125, 
the classical JNK inhibitor, exerts off-targets effects on AMPK-regulating phosphatases (e.g.: 
PP2C). 
Thus, we think that the helpful Editor´s and Reviewer´s comments have substantially 
improved our manuscript. We hope that after addressing all the comments raised after our re-
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revised version, our manuscript is now suitable for acceptance in Gastroenterology. We are looking 
forward to your response. 
Sincerely yours,  
                                    
 
 
Francisco Javier Cubero     Christian Trautwein 
Point-by-point reply to Editors and Reviewers: 
 
Editorial Board:  
1. The important human data you show in Fig1A and B need to be compatible and interconnected, and so 
do the findings in mice and humans. It is important to show JNK activation biochemically in panel B 
because on one hand, Fig1A suggests activation yet Fig1B shows dramatic decrease in JNK1 and JNK2 
protein in the human DILI livers. How could this be? This also relates to point 1 highlighted by Reviewer 2. 
Its still difficult to tell which cells are positive for pJNK; also please include information as to which p-JNK 
antibody did you used and the site it recognizes (?pT183/Y185 which presumably recognizes both JNKs.) 
Therefore, it is essential to: (i) test pJNK in the human livers by immunoblotting. Is it only the inflammatory 
cells that are activated or is it both hepatocytes and other cells? What percent of the cells are p-JNK 
positive and have nuclear localization? (ii) In Fig1B: what patients were tested by immune blotting; please 
specify the DILI type for each lane, (iii) the mouse APAP experiments: it is important to show what 
happens to JNK1 and JNK2 and their phosphorylation in the APAP model and contrast that with the 
human findings. One potential issue might be the timing of when specimen are harvested. Definitive 
conclusions need to be provided. As it stands now, there is some mouse data but its not clear how that 
matches with human DILI (at least with regard to APAP-related DILI). 
 
Reply: We thank for the comments and apologize for the lack of clarity. In our revised version of 
the manuscript, we now clearly identified the samples that we used.  Liver biopsies from normal 
liver tissue were labeled as healthy controls (#C1-C4), whereas patients with different etiologies 
of DILI are also indicated (#1-4). The patients’ characteristics are summarized in Suppl. Table I 
and in Figure Legend 1. An experienced pathologists scored the percentage of p-JNK positive 
cells (hepatocytes vs. non-parenchymal cells; nuclear vs. cytoplasmic). Since most of the pJNK 
staining was nuclear, the percentage of nuclear staining per view field is shown (n=7-10). 
Interestingly, we found cytoplasmic JNK staining in ibuprofen-derived DILI liver biopsies.  
In summary, in healthy tissue (C1-C4) we found absence or minimal JNK activation. In 
contrast, DILI-ALF patients (1-4) displayed strong immune cell infiltration associated with pJNK 
positivity (Figure 1A). Thus, we performed immunoblotting of liver samples of ALF patients with 
anti-JNK1 and JNK2 antibodies (Figure 1B). DILI-ALF patients displayed increased JNK 
phosphorylation (pT183/Y185, Cell Signaling Antibody, page 3; Suppl. Material). Interestingly, 
we detected a differential pattern of JNK1 expression and increased JNK2 levels in livers of 
DILI-ALF patients (Figure 1B). 
 
We next investigated the similarity of mechanism in human ALF and APAP-derived liver 
injury in mice. Eight hours after injection of 500 mg/kg APAP, we collected all liver samples (at 
the same time in liquid nitrogen, which were stored at -80°C). Wt mice elicited activation of JNK 
(same antibody from CTS we used for human samples). Noticeably, mice with specific deletion 
of Jnk1 in hepatocytes (Jnk1Δhepa) displayed reduced pJNK. In contrast, JnkΔhepa livers showed 
strong JNK induction, which is explained by strong immune cell infiltration in these mice during 
APAP-induced liver injury (Figure 1E). Interestingly, we detected increased expression of JNK1 
and complete abrogation of JNK2 in JnkΔhepa in murine APAP. Altogether our results indicated 
that (1) JNK is strongly activated in all forms of DILI-induced ALF, (2) etiology-dependent not 
only hepatocytes but also immune infiltrating cells are pJNK positive and; (3) Hence, a 
dysregulation of JNK1 and JNK2 protein expression is characteristic of both human and murine 
DILI. This is also discussed on Page 18.  
 
  
2. Your cover letter mentions a 2004 paper by Zhou et al but this reference is not included in the reference 
list and does not appear to be in PubMed (unless we missed it). What is the overlap between this paper 
and what is shown in this current manuscript. Related to this, if results related to JNK1-delta are planned 
for another manuscript, they really should be part of this paper.  
Point by Point Response
 
Reply: We are sorry for the misunderstanding. The paper we cite is Zhao et al (Gut, 2014). In 
this paper we showed that JNK1 in hepatocytes has no impact on the progression of CCl4–
induced toxic liver injury, while JNK1 is important for trans-differentiation of hepatic stellate cells 
(HSCs) and fibrogenesis. Therefore, we believe that there is no overlap between the two 
manuscripts. However, our findings are very important in light of our previous publication, first 
demonstrating the specific function of JNK1 in HSCs, and now the combined function of JNK1 
and JNK2 in hepatocytes during CCl4–induced liver injury. We also discussed these findings in 
different cell types, in the discussion section of the revised version of the manuscript (see page 
18). 
 
Its a bit strange to move from JNK1-delta (Fig1 and 2) to JNK2-delta (e.g., Fig3). 
 
In the present study we aimed to address specifically the combined functions of JNK1 and JNK2 
in hepatocytes in models of acute and chronic liver toxicity. For the APAP-induced liver injury 
model, we employed mice with hepatocyte-specific deletion of JNK1 (Jnk1hepa) and compared 
them with Jnk1hepa /Jnk2−/− (Jnkhepa) and the corresponding wildtype mice. The generation of 
these mice is specified in page 7 (Material and Methods). JNK2-/- mice were not included in our 
study since they exhibit a mild protection against APAP (Gunawan, 2006). In addition, mice with 
hepatocyte-specific deletion of JNK2 are not yet available.  
For the chronic toxic liver injury experiments with CCl4, we compared JNK2
-/- with 
Jnk1hepa /Jnk2−/− (Jnkhepa), and the corresponding wildtype mice. Here, Jnk1hepa were not 
included since these data have been already published as mentioned before (Zhao, 2014). 
 
3. Page 11 states that CYP2E1 is increased. However, Fig.2E does not really support this. Also, Suppl 
Fig2B show modest increase at best (similar to one of the immunoblot lanes) but its not clear how many 
livers were tested. Also, the staining of the CYP is rather diffuse in the JNK-delta which might be coming 
from damaged hepatocytes. It not clear how relevant is that data given the small changes. What is more 
important is what happens to JNKs, their phosphorylation and other down-stream targets. Quantification of 
the histologic liver injury should be included. You can probably remove this data to make room for other 
more relevant information.  
 
Reply: Thank you. Following the Editorial Board’ suggestion we deleted the CYP2E1 data.  The 
necrotic foci were quantified by our pathologist. This information is now included in Fig. 2. 
 
4. The purpose of the experiment shown in Suppl Fig7 is not clear. BM from both WT and JNK-del/hepa 
should be identical since JNK is presumably deleted only in hepatocytes. The results are not surprising. 
 
Reply: We agree with the Editors that the BMT experiments were expected and thus deleted 
Suppl. Fig. 7.  
 
5. The validation data (Fig5C) does not really match what is shown in Fig.5B (and some of the mRNA in 
Suppl Fig.8, such as PCNA, does not match what is shown in Fig.5C). Biologically meaningful conclusions 
(if indeed there are molecular differences unless basal conditions) need to be clearly shown. This is also 
compounded by what is shown in Suppl Fig8B,C (panel C does not show the BrdU for the delta-hepa and 
panel D is shown but not referred to in the text or explained) and stated at the top of page 14 of the 
manuscript.  
 
Reply: We revisited the Gene Array analysis and the samples we used for the validation. 
We summarized the findings using the Ingenuity Pathway Analysis™ (IPA) clearly showing that 
combined deletion of JNK1 and JNK2 in hepatocytes affect the expression of genes associated 
with cell death and proliferation, as well as inflammation. We found higher expression of 
pSTAT3, Saa2 and c-myc (cell cycle), and decreased BclXL and Bad (apoptosis) in JNKΔhepa 
livers (n=3-5). 
We also corrected Suppl. Fig. 9 (former 8) and clearly found reduced BrdU-positive 
proliferating cells (and thus cell cycle activity) in 48h plated JnkΔhepa hepatocytes (Suppl. Fig. 
9C+D).  
 
6. Text refers to Supp Fig9 C+D but the figure shows only panel A. There is also misnumbering related to 
Suppl Fig10 which made following the text difficult. 
 
Reply: Thank you. This has been now corrected and the former Supp. Fig. 10 deleted.  
 
7. Caspase activation needs to be shown biochemically (as related to the text on page 15). Also, 
quantification of the TUNEL data should be included (numbers can be included below the panels to 
minimize the use of space, with p values) 
 
Reply: We have included the TUNEL quantification and caspase-3 activity (fold induction). This 
is the new Figures 6D-E. We moved the Ann V/EtH III staining and quantification to Suppl. Fig. 
10. 
 
8. The protection of Rip3-/- hepatocytes from APAP does not mean that SP600125 effect is mediated by 
RIP3. What happens if you added this compound to RIP3-/- hepatocytes? You can probably remove this 
data to have more space to focus on more relevant information. 
 
Reply: Thank you for your comment, as suggested by the reviewer we deleted the data. 
 
9. One key missing piece remains to be the mechanism. One of your more interesting findings is what 
appears to be direct or indirect regulation of AMPK by JNK absence even under basal conditions (Fig7D: 
compare lane 1 with lanes 2 and 3 for pAMPK, assuming this is reproducible; AMPK levels should also be 
shown). It appears that the SP is acting by inhibition of a phosphatase that is then allowing compensatory 
phosphorylation of proteins such as AMPK. If AMPK is protective then you should be able to show that 
experimentally. Hence, the mechanism needs to be explored further with additional data provided. The 
conclusion should state that SP has off-target effect on AMPK (if that is conclusively shown, which you 
would need to provide experimentally). Related to this, it would be important to include a schematic as the 
last panel of Fig7 (Fig7F can be move to the supplemental section) that summarizes your findings. 
 
Reply: Thank you for this important point. Based on your suggestions we included several new 
experimental approaches. First, we investigated AMPK signaling. Interestingly, AMPK activity 
was abrogated after APAP challenge in control and JnkΔhepa animals. Total AMPK levels were 
also affected by APAP treatment. Strikingly, APAP treatment caused a decline in total AMPK 
levels in Wt and dramatically in JnkΔhepa livers. In contrast, co-treatment with SP600125, 
reversed the APAP-mediated effect on pAMPK and AMPK levels in both Wt and JnkΔhepa 
animals. Next, we examined whether lower AMPK levels correlated with JNK activity. APAP 
treatment increased JNK in Wt and, to a stronger extent, in JnkΔhepa livers, an effect blocked by 
co-treatment with SP600125. 
Collectively, these data suggest that; (1) SP600125 exerts an off-target effect on AMPK, 
and; (2) The protective effect of SP600125 occurs in liver parenchymal cells. These data are 
now part of the new Figure 7D+E. We also discuss our results on page 19, indicating that the 
off-target effect of SP600125 might be a protein phosphatases such as 2C (PP2C) which 
negative regulate AMPK signaling, preventing the dephosphorylation of AMPK. 
 
Additionally, we confirmed the protective role of AMPK by testing the in vivo the effects of 
pharmacological blockade of AMPK using [20 mg/kg] Compound C (CC), a cell-permeable 
AMPK inhibitor. As shown in the Fig. for Reviewers only, control and JnkΔhepa animals were 
challenged with APAPSP600125 for 8h. One hour before APAP injection, mice received CC [20 
mg/kg] i.p.. Inhibition of AMPK by CC resulted in increased areas of necrotic foci in control and 
to a larger extent in JnkΔhepa liver. This effect was attenuated by SP600125. Altogether these 
data indicate a protective effect exerted by AMPK in murine APAP-induced liver injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. With regard to point #2 raised by Reviewer 2, it appears that SP acts directly on, and protects, 
hepatocytes. Therefore, this will likely address the Reviewer concern though effects on non-parenchymal 
cells are indeed possible.  
  
Reply: We agree with Reviewer 2. Increased JNK phosphorylation in JnkΔhepa mice (see Figures 
1 and 7, completely different samples, and replicated at least 3 times) clearly demonstrates that 
JNK in infiltrating cells in involved in APAP-induced liver injury. This is also discussed in the 
discussion section (Figure 7E).  
 
11. Minor issues: (a) for the sizing bars in the images (gross, H&E, immunofluorescence), please do not 
include the size in the image since it will not read well when the figure is reduced (the size should be 
stated in the legend), (b) Please add the Mr sizes to the blots as per our Instructions to Authors, (c) 
Fig.1A: the red arrows are difficult to see, (d) Fig.2C (right lower panel): please indicate in the legend that 
the dotted area represents a necrotic focus, (e) no need to use so many decimals in Fig.5B (e.g., 8.2 
instead of 8.172), (f) CJUN should probably be cJUN, JUND should be JunD, (f) brackets in Fig7E don't 
match the lanes. 
 
Reply: Thank you; we have corrected these points. 
 
 
Reviewer #1:  
The authors attempted to address the two important issues (e.g. Jnk targets and context-dependent action 
of Jnk in the liver) by performing additional experiments, and the new data partially provide answers. Even 
though the answers remain largely unknown, the findings in this work indeed show that hepatocyte Jnk1 
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In vivo treatment with CC exacerbates APAP-induced liver injury
in mice with combined JNK1 and JNK2 deletion in hepatocytes.
Representative H&E staining of liver sections collected from the
same mice sacrificed 8h after APAPSP600125 treatment.
Compound C (CC) was administered i.p. one hour before.
Micrographs were examined by an experienced pathologist. Scale
bars 200m.
and 2 act together to protect against some types of liver injury, which is interesting. They also significantly 
modified the text to avoid overstatements of their data.  
 
Reply: Thank you for your comments. In this revised version we further investigated the 
mechanism by which JnkΔhepa mice elicit increased liver injury. Interestingly, AMPK activity was 
abrogated after APAP challenge in control and JnkΔhepa animals. Noticeably, APAP treatment 
caused a decline in total AMPK levels in Wt and dramatically in JnkΔhepa livers. In contrast, co-
treatment with SP600125, reversed the APAP-mediated effect on pAMPK and AMPK levels in 
both Wt and JnkΔhepa animals. Next, we examined whether lower AMPK levels correlated with 
JNK activity. APAP treatment increased JNK in Wt and, to a stronger extent, in JnkΔhepa livers. 
This effect was blocked by co-treatment with SP600125.  
Collectively, these data suggest that SP600125 exerts an off-target effect on AMPK. This 
effect might be mediated via a protein phosphatases such as 2C (PP2C) which negatively 
regulates AMPK signaling, preventing the dephosphorylation of AMPK. Certainly, these 
interesting observations need to be further confirmed. 
 
 
Reviewer #2:  
This is a resubmitted manuscript studying the role of JNK1 and JNK2 in drug and toxin-induced liver injury 
and fibrosis. The authors have addressed the concerns raised from previous reviews. This reviewer still 
has a couple of comments. 
 
Specific comments: 
 
Figure 1A shows increased JNK expression in DILI patients. However, JNK1 and JNK2 expression seems 
to decrease in DILI samples by WB analysis. The authors should explain this discrepancy appropriately.  
 
Reply: This is an important point. We further studied pJNK activation in liver samples of patients 
with different DILI etiologies. Increased pJNK in nuclei of hepatocytes and infiltrating cells was 
characterized by immunohistochemistry but also by Western blot analyses (new Figure 1). While 
we observed increased JNK2 expression (new Antibody Cell Signalling, replicated at least 3 
times), we detected differential expression of JNK1 in the same samples, indicating a 
deregulation of JNK1 expression. 
 
Figure 7: JNK1-d-hepa and JNK-d-hepa should express JNK1 in non-parenchymal cells. Therefore, not 
only JNK-independent effect, the protective effect of SP600125 on these animals might also be due to the 
effect on non-parenchymal cells, suggesting JNK1 in non-parenchymal cells play an important role in the 
liver pathology. This has to be discussed.  
 
Reply: We absolutely agree with the Reviewer. Indeed, we investigated murine APAP-induced 
liver injury in Figures 1 and 7 with respect to JNK activation (pJNK, JNK, JNK1 and JNK2). This 
revised version of the manuscript clearly shows that the infiltrating cells are involved in APAP-
induced liver injury, which is especially evident in JnkΔhepa animals. At present we have no 
functional data on the role of JNK activation in immune cell. This finding is now also discussed in 
the discussion section (pages 18-20).   
 
Minor comments: 
 
p. 12, l.18, "CD11" should be "CD11b". 
 
Reply: Thank you, we have renamed it. 
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Abstract:  
Background&Aims: c-Jun N-terminal kinase (JNK)1 and JNK2 are expressed in 
hepatocytes and have overlapping and distinct functions. JNK proteins are activated, via 
phosphorylation, in response to acetaminophen- or CCl4-induced liver damage; the level of 
activation correlates with the degree of injury. SP600125, a JNK inhibitor, has been 
reported to block acetaminophen-induced liver injury. We investigated the role of JNK in 
drug-induced liver injury (DILI) in liver tissues from patients and in mice with genetic 
deletion of JNK in hepatocytes. Methods: We studied liver sections from patients with DILI 
(due to acetaminophen, phenprocoumon, non-steroidal anti-inflammatory drugs or 
autoimmune hepatitis), or patients without acute liver failure (controls), collected from a 
DILI Biobank in Germany. Levels of total and activated (phosphorylated) JNK were 
measured by immunohistochemistry and western blotting. Mice with hepatocyte-specific 
deletion of Jnk1 (Jnk1Δhepa) or combination of Jnk1 and Jnk2 (JnkΔhepa), as well as Jnk1-
floxed C57BL/6 (control) mice, were given injections of CCl4 (to induce fibrosis) or 
acetaminophen (to induce toxic liver injury). We performed gene expression microarray, 
and phosphoproteomic analyses to determine mechanisms of JNK activity in hepatocytes. 
Results: Liver samples from DILI patients contained more activated JNK, predominantly in 
nuclei of hepatocytes and in immune cells, than healthy tissue. Administration of 
acetaminophen to JnkΔhepa mice produced a greater level of liver injury than that observed 
in Jnk1Δhepa or control mice, based on levels of serum markers and microscopic and 
histologic analysis of liver tissues. Administration of CCl4 also induced stronger hepatic 
injury in JnkΔhepa mice, based on increased inflammation, cell proliferation, and fibrosis 
progression, compared to Jnk1Δhepa or control mice. Hepatocytes from JnkΔhepa mice given 
acetaminophen had an increased oxidative stress response, leading to decreased 
activation of AMPK, total protein AMPK levels, and pJunD and subsequent necrosis. 
5 
 
Administration of SP600125 before or with acetaminophen protected JnkΔhepa and control 
mice from liver injury. Conclusions: In hepatocytes, JNK1 and JNK2 appear to have 
combined effects in protecting mice from CCl4- and acetaminophen-induced liver injury. It 
is important to study the tissue-specific functions of both proteins, rather than just JNK1, in 
the onset of toxic liver injury. JNK inhibition with SP600125 shows off-target effects. 
 
KEYWORDS: APAP, mouse model, gene regulation, pharmacological treatment 
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Introduction 
Acute and chronic liver injury is a growing worldwide problem despite the recent 
advances for the treatment of HBV and HCV infection. Especially, the frequency of toxic 
insults such as alcohol, drugs or obesity is even increasing in the Western World. In the 
liver, toxic injury triggers death signalling pathways, which may cause apoptosis, necrosis 
or pyroptosis of hepatocytes1, 2. However, the exact pathomolecular mechanisms 
determining the mode of cell death are not completely understood.  
Liver injury of different aetiology activates JNK - members of the MAPK family. 
Whereas Jnk3 is exclusively expressed in the central nervous system, testis and heart, 
Jnk1 and Jnk2 are expressed in hepatocytes eliciting redundant but also distinct 
functions3-5. In order to characterise the compound functions of the JNK genes e.g. in 
hepatocytes, cell type-specific deletion of both Jnk1 and Jnk2 is essential. At present, 
most studies have been performed only using single knockout mice or JNK-specific 
inhibitors. 
Toxic liver injury – acute or chronic – activates the oxidative stress response. 
Typical examples are acute liver damage after APAP intoxication or chronic liver injury by 
repetitive CCl4-injection. APAP-induced injury is related to the formation of highly reactive 
metabolites through CYP2E1. These toxic compounds are normally conjugated and 
inactivated by glutathione (GSH). In overdose conditions, the conjugation of the reactive 
metabolites leads to GSH depletion and thus enhances the generation of oxidative (ROS) 
and nitrosative species (RNS) triggering hepatocyte injury6. N-acetylcysteine (NAC) has 
been the standard antidote for APAP-induced liver intoxication7. NAC exerts its therapeutic 
effects by restoring depleted hepatic glutathione levels, and thus preventing the 
accumulation of oxidant species7.  
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Earlier results demonstrated that JNK is strongly activated by APAP correlating with 
the degree of liver injury8. Additionally, in vivo experiments evidenced that JNK inhibition 
blocked APAP-induced liver injury9. Thus JNK seems to play an essential role in APAP-
induced hepatic damage, supporting the possibility of using JNK inhibitors as a therapeutic 
approach.   
Kluwe et al10 first suggested that JNK is crucial for chronic CCl4-intoxication, 
associated with hepatocyte damage, necrosis, inflammation, and end-stage liver fibrosis. 
JNK activation is not only restricted to hepatocytes. Indeed, we found that Jnk1 is 
particularly important for trans-differentiation of hepatic stellate cells (HSCs) since Jnk1 
deletion in HSCs reduces fibrogenesis after chronic CCl4-intoxication11.  
In the present work we aimed to address specifically the yet unexplored dual role of 
Jnk1 and Jnk2 in hepatocytes in models of acute and chronic toxic liver injury in mice, and 
in patients with DILI. Based on the previous studies, we hypothesized that JNK1 and JNK2 
in hepatocytes have redundant functions. For this purpose, we generated JnkΔhepa mice 
and studied the functional role of the JNK genes in APAP- and CCl4-induced toxic liver 
injury in vivo and in culture using primary hepatocytes.   
 
Material and Methods 
Generation of mice, animal experiments and human samples 
Alb-Cre and Jnk2-deficient mice in a C57BL/6 background were purchased from The 
Jackson Laboratory (Bar Harbor, ME). Mice with a floxed allele of Jnk1 were constructed 
by using homologous recombination in ES cells and backcrossed to the C57BL/6J strain 
as previously described12, 13. These mice were then crossed with Jnk2-deficient mice to 
create Jnk1LoxP/LoxP /Jnk2−/− mice. Genomic DNA was examined using PCR amplimers (5′-
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CTCAGGAAGAAAGGGCTTATTTC-3′ and 5′-GAACCACTGTTCCAATTTCCATCC-3′) to 
distinguish between the control floxed (Jnk1+ ,Jnk1f), and deleted (Jnk1Δ) alleles.  
Animal experiments were carried out according to the German legal requirements and 
animal protection law and approved by the authority for environment conservation and 
consumer protection of the state of North Rhine-Westfalia (LANUV, Germany).  Induction 
of liver fibrosis was performed in 7-8 week-old age-matched male mice (n=9-10 per group) 
using CCl4-injection every 3 days for 4 weeks (0.6 mL/kg, i.p.). Control animals were 
injected with corn oil. The D-Galactosamine (GaIN)/Lipopolysaccharide (LPS) 
administration was performed in 7-8 weeks-old male control and Jnkhepa male animals to 
induce acute hepatitis. 30 minutes prior to the LPS-injection (20 g/kg, i.p.), GaIN (800 
g/kg, i.p.) was injected. Mice were sacrificed 8 h after LPS injection. We also performed 
the APAP-induced liver injury model. After fasting overnight, mice were injected with APAP 
(500 mg/kg), and sacrificed 8h after treatment. SP600125 was injected 2h (pre-treatment) 
or at the same time with APAP (co-treatment) at a dose of 30 mg/kg, i.p.). 
Liver paraffin sections were obtained from patients with confirmed diagnosis of DILI 
(paracetamol, phenprocoumon, non-steroidal inflammatory drugs or autoimmune hepatitis) 
from the Department of Gastroenterology of the University Hospital Essen, Germany. 
Patients’ clinico-pathologic characteristics were analyzed, summarized and represented in 
Suppl. Table I.  
 
Statistical analysis 
All data are expressed as mean ± standard error of the mean. Statistical significance was 
determined by two-way analysis of variance (ANOVA) followed by a Student’s t test or by 
one-way ANOVA followed by a Newman-Keuls multicomparison test. P values less than 
0.05 were considered to be significant.  
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Results 
Expression of JNK in human acute liver failure. Drug-induced liver injury (DILI) is the most 
common cause of ALF14. First, we studied serum parameters of patients with different ALF 
etiologies. As indicated in Suppl. Table I, livers from patients suffering from paracetamol 
(1), phenprocoumon (2), non-steroidal anti-inflammatory drugs (NSAID) (3), and 
autoimmune hepatitis (AIH)-induced ALF (4) were investigated. We observed that the most 
prominent increase in transaminases was evident in patients with APAP- and AIH-induced 
ALF, while NSAID- and phenprocoumon-induced ALF patients showed less pronounced 
changes in serum markers. However, all serum samples showed impaired liver function as 
evidenced by changes in bilirubin and blood coagulation parameters (Suppl. Table I). 
Noticeably, the patient with APAP intoxication showed dramatically increased GLDH levels 
and blood coagulation parameters (Suppl. Table I).  
We next investigated the JNK activation pattern in these ALF liver samples (1-4) 
and normal healthy tissue as control (C1-C4) by performing pJNK staining and 
quantification (Figure 1A, Suppl. Fig. 1A). Absence or minimal activation of JNK was 
detectable in healthy tissue. Liver histology of the APAP patient in comparison with the 
other liver samples showed lower infiltration of immune cells and JNK phosphorylation 
mainly restricted to hepatocytes (Figure 1A). In contrast, liver samples obtained from other 
ALF subtypes displayed strong immune cell infiltration associated with pJNK positivity 
(Figure 1A). In the liver, two JNKs are expressed, JNK1 and JNK2. Thus, we performed 
Western Blot analysis of liver samples of ALF patients with anti-JNK1 and JNK2 antibodies 
(Figure 1B). Normal tissue displayed mild JNK phosphorylation, whereas ALF patients 
displayed higher JNK activation. Interestingly, we detected a differential pattern of JNK1 
expression and increased levels of JNK2 in DILI-ALF patients (Figure 1B). 
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Deletion of JNK1 and JNK2 in hepatocytes. We next aimed to characterize the functional 
relevance of JNK activation during toxic liver injury. We generated mice with specific 
deletion of Jnk1 in hepatocytes (Jnk1Δhepa) and combined Jnk1 and Jnk2 knockout mice in 
hepatocytes (JnkΔhepa) (Figure 1C; Suppl. Fig. 1B+C). To exclude the possibility that 
JnkΔhepa mice exhibited a phenotype under basal conditions we carefully examined 6-8 
weeks female and male Jnk1Δhepa and JnkΔhepa mice.  Liver histology, serum parameters as 
well as body weight, and liver versus body weight ratio presented values of normal healthy 
mice (Suppl. Fig. 2A-F). 
Since the human data demonstrated that JNK is strongly activated mainly in 
hepatocytes during APAP-induced ALF, we sought to translate and compare the human 
ALF results with APAP-derived liver injury in mice. Eight hours after injecting 500 mg/kg 
APAP, livers of Wt mice elicited JNK activation. Noticeably, mice with specific deletion of 
Jnk1 in hepatocytes (Jnk1Δhepa) displayed reduced pJNK, whereas JnkΔhepa mice showed 
strong JNK1 induction, suggesting that the infiltrating compartment is responsible for the 
activation of the MAPK in experimental murine APAP-derived injury (Figure 1D). 
Furthermore, we detected JNK1 and JNK2 protein expression after APAP in Wt, while the 
levels of JNK1 were strongly induced in JnkΔhepa mice. Expectedly, JNK2 expression was 
abrogated in mice lacking JNK in hepatocytes.  
 
JnkΔhepa mice are sensitized towards acetaminophen-induced liver injury. JnkΔhepa showed 
significantly exacerbated APAP-induced ALF as evidenced by significantly increased AST, 
ALT and GLDH levels (Figure 2A). No differences were found in liver versus body weight 
ratio (Suppl. Fig. 3A). Macroscopically, the surface of JnkΔhepa livers showed severe signs 
of haemorrhagic bleeding, and microscopically the liver was severely injured with presence 
of large necrotic foci (Figure 2B-D, respectively).  
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Acetaminophen is metabolized via CYP2E1 to the electrophilic reactive product N-
acetyl-p benzoquinone imine (NAPQI)15. Interestingly, we detected a tendency towards in 
F2-isoprostanes - a direct marker of oxidative stress16 - and significantly reduced levels of 
p38 expression in JNK-depleted hepatocytes after APAP treatment (Figure 2E, Suppl. Fig. 
3B+C). 
These striking results in APAP-induced DILI prompted us to investigate whether the 
function of JNK1 and JNK2 is universal or dependent on the context of hepatic injury. 
Thus, we treated JnkΔhepa mice with D-GalN combined with endotoxin (LPS). 
Unexpectedly, no differences were observed after D-GalN/LPS treatment in survival, 
serum markers of liver injury, tissue injury or liver versus body weight ratio between both 
control groups and JnkΔhepa animals. These data suggest that JNK1 and JNK2 in 
hepatocytes play a prominent protective role especially during toxic liver injury (Suppl. Fig. 
4A-E). 
 
CCl4–induced chronic liver injury is worsened in mice with combined deletion of Jnk1 and 
Jnk2 in hepatocytes. Since we previously showed that JNK1 in hepatocytes has no impact 
on the progression of CCl4-induced toxic liver injury11, we questioned whether compound 
function of JNK1 and JNK2 in hepatocytes is implicated in chronic toxic liver injury. 28 
days after repetitive CCl4 treatment, JnkΔhepa livers showed larger numbers and size of 
necrotic areas compared with Jnk2-/- or Wt control mice (Figure 3A, Suppl. Fig. 5A). 
JnkΔhepa livers showed increased collagen deposition as evidenced by Sirius red staining, 
CollagenIA1 and α-smooth muscle actin (αSMA) protein and mRNA expression (Figure 
3B-E, Suppl. Fig. 5B-E). Additional liver fibrosis markers such as hydroxyproline 
quantification, Timp1 and Mmp2 (Figure 3F, Suppl. Fig. 5F) suggested a protective role of 
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combined JNK1 and JNK2 activation in hepatocytes during chronic toxic CCl4–induced 
liver injury. 
 
Aggravated cell death and compensatory proliferation in JnkΔhepa liver after repetitive CCl4–
injection. To better characterize our findings, we analyzed parameters of cell death and 
proliferation. TUNEL- and cleaved Caspase3-positive nuclei were significantly enhanced 
28 days after CCl4 treatment in JnkΔhepa livers compared with Jnk2-/- or control mice (Figure 
4A-C). Concomitantly, compensatory proliferation examined by Ki-67 staining was 
significantly increased in JnkΔhepa livers (Figure 4D+E). These results were strengthened 
by higher mRNA expression of cell cycle markers such as Pcna (mRNA) and up-regulation 
of PCNA and CyclinD protein levels in JnkΔhepa compared with Jnk2-/- or control livers 
(Figure 4F, Suppl. Fig. 6A+B). Thus loss of JNK1 and JNK2 in hepatocytes resulted in 
stronger cell death accompanied by an increased proliferative response in the liver. 
 
The inflammatory response is increased in JnkΔhepa livers. Chronic inflammation triggers 
progression of liver fibrosis17. After 28 days of CCl4-injection, we found a significant 
increase in CD11b- and F4/80-positive cells, putative macrophages/Kupffer cells, in 
JnkΔhepa compared with Jnk2-/- and control livers (Suppl. Fig. 7A+B). Additionally, JnkΔhepa 
livers displayed stronger expression of inflammatory markers such as IL1α, IL1β, Mcp1 
and Tnfα (Suppl. Fig. 7C-F). Hence, loss of JNK1 and JNK2 in hepatocytes caused severe 
inflammatory liver injury and fibrosis.  
 
Gene and protein profile of JnkΔhepa livers and hepatocytes in basal conditions. To study 
the impact of Jnk deletion on gene expression in liver and hepatocytes, we performed 
Affymetrix GeneChip microarray analysis of liver and primary hepatocytes isolated from 8 
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week-old control and JnkΔhepa mice. This comparison revealed significant changes (-
1.5<FC>1.5) in the transcript expression of 355 genes which were up-regulated (197 in 
liver and 158 in hepatocytes) and 448 down-regulated (171 in liver and 277 hepatocytes) 
in JnkΔhepa mice (Suppl. Fig. 8A+B). We first performed hierarchical clustering of the JNK 
substrates commonly up- or down-regulated in both livers and hepatocytes of JnkΔhepa 
mice. Interestingly, we found significantly reduced transcript levels of JNK target genes 
including transcription factors Atf, JunD or Fos and apoptotic markers (Bcl2l13 and Bid), 
and up-regulation of Gadd45b, Saa2 and Cmyc (Figure 5A). Moreover, Ingenuity Pathway 
Analysis™ (IPA) demonstrated that combined deletion of JNK1 and JNK2 in hepatocytes 
affected the expression of genes associated with cell death and proliferation (Cdkn1a, Atf, 
myc), inflammation (Smad7, IL18, Ctgf, Cox6b2) as well as metabolism (ABCC4, 
CYP2B13) (Figure 5B).  
To validate the main findings of the microarray analysis, protein and mRNA 
expression was analyzed in both livers and freshly isolated primary hepatocytes from 8 
week-old Wt, Jnk1Δhepa and JnkΔhepa mice revealing enhanced expression of pSTAT3, Saa2 
and c-myc (cell cycle), and down-regulation of BclXL and Bad (apoptosis). As expected, 
lack of Mapk9/Jnk2 expression was found in JnkΔhepa mice (Figure 5C, Suppl. Fig. 8C+D).  
 
Morphological changes and mitochondrial damage are aggravated in APAP-treated 
JnkΔhepa primary hepatocytes. The acute and chronic toxic models suggested that JNK1 
and JNK2 have synergistic functions for hepatocyte protection. We aimed to better define 
the molecular mechanisms explaining our findings in vivo, in primary control (Wt) and 
JnkΔhepa hepatocytes. Liver cells were cultured for up to 48h without treatment (Suppl. Fig. 
9A). Lack of Jnk expression did not affect viability compared with WT hepatocytes (Suppl. 
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Fig. 9B). However, basal cell cycle activity was reduced in JnkΔhepa compared to control 
hepatocytes (Suppl. Fig. 9C+D).  
Next, we investigated the mechanism underlying the strong phenotype induced by 
APAP [10 mM] in JnkΔhepa hepatocytes for up to 48h. 12h after APAP treatment JnkΔhepa 
hepatocytes evidenced cytoplasmic projections, loss of cell-cell contact and detachment in 
contrast to polyhedral rounded shaped control hepatocytes (Figure 6A). Up to 24h upon 
treatment, nuclear condensation or fragmentation was significantly stronger in JnkΔhepa 
compared to control hepatocytes (not shown).  
SP600125, an anthrapyrazolone specific JNK inhibitor, has been shown to protect 
against APAP-induced ALF in mice18. Unexpectedly, control and JnkΔhepa-APAP treated 
hepatocytes were protected to the same extent by co-administration of SP600125+APAP 
(Figure 6A). APAP mediates its toxic effect by forming highly reactive metabolites. 
Concomitant with the morphological changes, we detected a significant increase in 
mitochondrial ROS in APAP-treated JnkΔhepa compared with control hepatocytes. 
Additionally, SP600125 significantly reduced the changes in mitochondrial membrane 
potential in both control and JnkΔhepa APAP-treated hepatocytes (Figure 6B, Suppl. Fig. 
10A).  
 
APAP exacerbates necrotic cell death in JnkΔhepa-primary hepatocytes. TUNEL staining 
evidenced significant lower cell survival of APAP-treated JnkΔhepa compared with control 
hepatocytes 12h after treatment (Figure 6C). Cell death was significantly reduced after 
SP600125APAP co-administration in control and JnkΔhepa hepatocytes (Figure 6C+D). We 
next sought to define the mode of cell death in APAP-treated hepatocytes. We first tested 
Caspase3 activity before and after APAP administration including SP600125. APAP-
treatment in any combination and at different time points did not significantly change 
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Caspase3 activity (Figure 6E). This result was further confirmed by Caspase3 
immunostaining (not shown). To detect the relevance of necrotic cell death, we performed 
Annexin V/Ethidium Homodimer III staining. The amount of double positive (i.e. necrotic) 
hepatocytes were significantly higher in JnkΔhepa compared with control hepatocytes, while 
SP600125 blocked necrosis in both control and JnkΔhepa hepatocytes (Suppl. Fig. 10B+C). 
Receptor interacting protein 3 (RIP3) plays an essential role in mediating necrotic 
cell death. We studied RIP3 and RIP1 expression in WT and JnkΔhepa hepatocytes before 
and after APAPSP600125 co-treatment (Figure 6F). APAP treatment had no effect on 
RIP3, but stimulated RIP1 expression in both control and was strongly induced in JnkΔhepa 
hepatocytes. SP600125+APAP co-treatment strongly reduced RIP3 expression to 
comparable levels in control and JnkΔhepa hepatocytes, while the decreasing effect on the 
RIP1 protein was more prominent in control hepatocytes (Figure 6F).  
To characterize the specificity of our findings, we included pERK and p65 
expression in our analysis. APAP treatment stimulated both pERK and p65 expression 
independent of SP600125 co-treatment, suggesting that both pathways are of minor 
relevance in explaining the effect on necrosis (Figure 6F). To further confirm this result we 
tested pJNK and p-cJUN expression before and after treatment. As shown in Figure 6F, 
APAP- induced pJNK and p-cJUN activation in control hepatocytes, while SP600125 
blocked JNK, but not cJUN phosphorylation. In contrast, no significant pJNK and p-cJUN 
expression in either treatment conditions was evident in JnkΔhepa hepatocytes.  
 
In vivo treatment with SP600125 suppresses APAP-induced liver injury in mice with 
compound deletion of JNK1 and JNK2 in hepatocytes. To validate the in vitro findings, we 
studied SP600125 co- and pre-administration with APAP in JnkΔhepa animals in vivo. Co-
treatment with the JNK inhibitor provided protection in control and Jnk1Δhepa but also in 
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JnkΔhepa mice against APAP-induced liver injury (Figure 7A-C). To exclude the possibility 
that SP600125 affects APAP metabolism, we pre-administered SP600125 to control, 
Jnk1Δhepa and JnkΔhepa mice, and two hours later we injected APAP (Figure 7A-C). 
However, pre-administration did not affect the protective effect. Noticeably, the number of 
necrotic foci was largely reduced in liver parenchyma of SP600125 co- or pre-treated 
JnkΔhepa mice (Figure 7B+C).  
Since our results suggested that SP600125 protects against APAP-induced liver 
injury via JNK-independent mechanisms, we explored other pathways associated with 
APAP-toxicity. Sabery and colleagues19 recently showed that the interplay between PKC 
and JNK mediates APAP-induced liver injury. PKC activation increased after APAP 
treatment and was attenuated by SP600125 co-administration in Wt livers (Figure 7D). 
Moreover, AMPK activity – protective against APAP hepatotoxicity – was abrogated after 
APAP challenge in control and JnkΔhepa animals. Total AMPK levels were also affected by 
APAP treatment. Noticeably, APAP treatment caused a decline in total AMPK levels in Wt 
and dramatically in JnkΔhepa livers. In contrast, co-treatment with the classical JNK inhibitor, 
SP600125, reversed the APAP-mediated effect on pAMPK and AMPK levels in both Wt 
and JnkΔhepa animals.  
Next, we examined whether lower AMPK levels correlated with JNK activity. APAP 
treatment increased JNK in Wt and, to a higher extent, in JnkΔhepa livers, an effect blocked 
by co-treatment with SP600125 (Figure 7D). Collectively, these data suggest that; (1) 
SP600125 exerts an off-target effect on AMPK, and; (2) the protective effect of SP600125 
occurs in liver parenchymal cells. 
 
Lack of JunD activation in APAP-treated JnkΔhepa murine hepatocytes. We performed a set 
of quantitative phosphoproteomics experiments to characterize proteins which could be 
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differentially phosphorylated after APAP treatment in control and JnkΔhepa hepatocytes 
(Suppl. Fig. 11A). Amongst several differentially phosphorylated proteins, which we could 
not validate by western blot due to lack of commercially available phospho-antibodies, our 
screening approach identified JunD – a known JNK nuclear substrate – to be substantially 
less phosphorylated in APAP-treated JnkΔhepa hepatocytes (Figure 7E). In addition, we 
investigated overall phosphorylation of MAPKs, which are known substrates of JNK, using 
a MAPK-substrate specific antibody (Suppl. Fig. 11B). This approach revealed at least 
nine proteins with reduced phosphorylation in APAP-treated JnkΔhepa hepatocytes. The 
identity of these proteins was estimated by comparison of their appropriate molecular 
weights with known JNK substrates (Suppl. Fig. 11B). In summary, these results 
demonstrate substantially attenuated phosphorylation of JunD and other proteins in APAP-
treated JnkΔhepa hepatocytes, which need to be identified in future studies. These findings 
indicate that a JNK-JunD dependent mechanism might be involved in protecting against 
APAP-induced liver injury.  
 
Discussion 
Acetaminophen- and CCl4-induced liver injury have been extensively studied since 
APAP overdose is the leading cause of DILI in the United States and accidental CCl4 
ingestion still occurs14. An overwhelming amount of evidence demonstrated that JNK 
activation plays a major role in toxic liver injury20. Our first investigations using human DILI 
liver samples showed activation of JNK (pJNK) predominantly in nuclei of hepatocytes and 
in infiltrating cells. These results are in line with observations that JNK activation is not 
only limited to hepatocytes but also found in pro-fibrotic and inflammatory cells during 
progression of liver disease in humans and mice10, 11, 21.   
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Noticeably, our results suggest differential pattern of JNK1 expression, and 
increased JNK2 levels in human DILI-ALF liver biopsies compared with normal tissue. 
Furthermore, JNK activation was a common feature of murine APAP-induced liver injury 
not only in Wt but also especially in JnkΔhepa mice. Noticeably, the intense JNK 
phosphorylation as well as increased JNK1 expression in JnkΔhepa livers after APAP 
correlated with the dramatic increase in transaminases. These results suggest that JNK1 
phosphorylation in infiltrating cells and non-parenchymal cells correlates with the degree of 
liver injury. However, the functional role of these cell compartments during APAP-induced 
liver injury needs to be further addressed.  
As found in human samples, JNK1 and JNK2 protein expression was also 
dysregulated after APAP challenge in mice, indicating an analogous mechanism between 
human and murine DILI. Altogether our results indicated that (1) JNK is strongly activated 
in all forms of human DILI-induced ALF, (2) etiology-dependent not only hepatocytes but 
also immune infiltrating cells are pJNK positive and (3) hence, a dysregulation of JNK1 
and JNK2 protein expression is characteristic of both human and murine DILI. 
Additionally, our array analysis led us to the working hypothesis that JNK1 and 
JNK2 might have distinct and shared essential functions in hepatocytes. In the current 
study, we found that combined JNK1 and JNK2 deletion in hepatocytes triggers more 
severe liver injury, inflammation and progression after repetitive CCl4 injection. 
Interestingly, our previous publication revealed that JNK1 is involved in HSCs trans-
differentiation into collagen-producing myofibroblasts11, associated with reduced liver 
injury. Consequently, JNK2 expression is sufficient to rescue the loss of JNK1 in 
hepatocytes and protects from CCl4-mediated cell death.  
The prominent role of necrotic cell death in APAP-dependent liver injury has been 
shown in several studies22-26. Previous reports by the lab of Kaplowitz27 suggested that 
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disruption of JNK2, but not of JNK1, partially prevented APAP-induced liver injury, 
indicating that targeting JNK2 could be a promising therapeutic approach. In contrast, 
Henderson and collaborators found no differences in APAP- induced liver injury between 
Jnk1-/- and Jnk2-/- mice28. Our data demonstrate that lack of JNK1 and JNK2 expression in 
hepatocytes caused extensive necrosis within 8h after APAP injection. Concomitant with 
these findings, we observed a dramatic oxidative stress response in the liver of JnkΔhepa 
mice, associated with necrotic cell death22, 23. We excluded that apoptotic cell death plays 
a significant role in APAP-treated JnkΔhepa hepatocytes. Instead, we demonstrate that 
combined JNK1 and JNK2 activities are protective against APAP-induced necrotic cell 
death of hepatocytes by controlling the oxidative stress response.  
The observations found in APAP-induced liver injury were specific for this form of 
ALF, since we observed no differences in the acute hepatitis-D-GalN/LPS model between 
JnkΔhepa and control animals. This is in agreement with a recent study indicating that 
combined deletion of JNK1 and JNK2 in hepatocytes did not alter ConA- or LPS-induced 
liver injury29. However, hematopoietic deficiency in JNK1 and JNK2 prevented ConA-
induced liver injury by suppressing TNF production29. These findings clearly suggest that, 
under certain conditions (e.g. aetiology of liver disease), JNK activation in infiltrating cells 
rather than in hepatocytes is critical. Altogether these results suggest that the context-
specific activation of JNK in different cell-types during ALF is essential, and needs to be 
further defined.  
To better assess these results, we included the classical JNK inhibitor, SP600125, 
in our analysis. This compound has been reported to target the highly conserved ATP-
binding sites of JNK and protects from APAP-induced liver injury in vivo30. Surprisingly, 
SP600125 was found to confer protection not only to control but also to Jnk-deleted 
hepatocytes in vivo and in vitro. Moreover, pre-administration of SP600125 did not affect 
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APAP metabolism. These results suggested that the beneficial effect of SP600125 on 
APAP-induced liver injury likely results through off-target effects, e.g., on AMPK. 
Concomitant with previous reports19, we found decreased levels of pAMPK and a further 
decline of total AMPK levels – protective against APAP hepatotoxicity– in JnkΔhepa livers, 
indicating that survival pathways are reduced in animals with JNK deficiency in 
hepatocytes. Thus SP600125 might act on protein phosphatases such as 2C (PP2C) 
which negative regulate AMPK signalling, preventing the dephosphorylation of AMPK 
(Figure 7F).  
Additionally, we employed functional proteomics to map differential phosphorylation 
caused by APAP treatment in JNK-deficient hepatocytes. Our findings suggest repression 
of JunD activation, another protective element and part of the cell stress response, was 
further decreased in the absence of JNK in hepatocytes. Hence, the role of other kinases 
involved in necrotic cell death such as RIP3, RIP1 or MLKL are currently under intensive 
investigation24, 31. 
In summary, we demonstrate that combined JNK1 and JNK2 activation is essential 
to protect hepatocytes from acute and chronic toxic liver injury in vivo and in vitro. Our 
results show that JNK inhibition is a questionable treatment option for APAP-induced liver 
injury as the protecting effect of SP600125, the classical JNK inhibitor, is mediated by off-
target effects. Hence our results show that the cell-type specific function of JNK is a 
potential therapeutic target. However, the context-specific function needs to be defined 
before these options can be employed in the clinic. 
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Figure Legends 
Figure 1. Expression of JNK during human and murine drug-induced liver injury 
(DILI). (A) Activation of pJNK in liver samples of ALF patients with different aetiologies: 
normal liver tissue (C1, C2), paracetamol (1), phenprocoumon (2), autoimmune hepatitis 
(AIH) (3), and non-steroidal anti-inflammatory drug (NSAID) (4). Scale bars: 50m. 
Phospho-JNK positive nuclei were quantified as the average number of hepatocytes or 
infiltrating cells with dark brown DAB signal per view field of liver sections from healthy and 
DILI patients. (B) Immunoblotting for pJNK, JNK1 and JNK2 was performed in normal liver 
tissue (C1-C4) and in liver samples of DILI patients (1-4). (C) Protein expression of JNK1 
and JNK2 was assessed in primary hepatocytes (left panel) and livers (right panel) from 8 
week-old control (Wt), Jnk2-/-, Jnk1Δhepa and JnkΔhepa mice. Total JNK1 and JNK2 protein 
levels were determined in whole liver extracts. GAPDH was used as loading control. (D) 
Immunoblotting for pJNK, JNK1 and JNK2 was performed in liver samples from control 
(Wt), Jnk1Δhepa and JnkΔhepa mice treated with APAP for 8h (n=6). GAPDH was used as 
loading control. 
 
Figure 2. JnkΔhepa mice are sensitized towards acetaminophen-induced liver injury. 
(A) Serum ALT (left), AST (center) and GLDH (right) levels were determined 8h after 
APAP challenge in control (Wt), Jnk1Δhepa and JnkΔhepa livers (n=10). (B) Representative 
macroscopic view of a liver from each group. Scale bars: 10mm.  (C) Representative H&E 
staining of liver sections collected from mice sacrificed 8h after APAP challenge and 
examined by an experienced pathologist. Scale bars: 50m (upper panel) and 100m 
(lower panel), respectively. Dotted area represents a necrotic focus. (D) The area of 
necrosis was quantified in the same mice.  (E) Protein levels of pP38 were determined by 
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Western Blot in APAP-treated control (Wt) and JnkΔhepa livers. GAPDH was used as 
loading control. Data are expressed as mean±SEM (*p<0.05 and **p<0.01). 
 
Figure 3. Liver fibrogenesis is aggravated in JnkΔhepa after chronic CCl4 treatment. 
(A) Representative H&E staining of liver sections of control (Wt), Jnk2-/- and JnkΔhepa livers, 
28 days after repeated injections of CCl4. Corn-oil injections were used as controls. Scale 
bars: 100m. (B) Representative Sirius red staining of paraffin sections from the same 
livers. Scale bars: 100m. (C) A representative Collagen IA1 staining of frozen sections 
from the same mice is shown. Scale bars: 200m. (D) In addition, mRNA levels for 
Collagen IA1 and αSMA were determined by qRT-PCR. (E) Protein levels of αSMA were 
determined. GAPDH was used as a loading control. (F) Hydroxyproline contents were 
assessed in the same livers. Data are expressed as mean±SEM (*p<0.05 and ***p<0.001). 
 
Figure 4. Cell death and compensatory proliferation are exacerbated after combined 
deletion of JNK1 and JNK2 in hepatocytes. (A) Representative TUNEL staining 
performed on frozen liver sections (upper; Scale bars: 100m) and cleaved CASPASE3 
immunohistochemistry in paraffin sections (lower panel; Scale bars: 100m) of control 
(Wt), Jnk2-/- and JnkΔhepa livers after 4 weeks of repeated CCl4 injections are shown. 
Quantification of TUNEL- (left) (B) and Caspase3 enzyme activity (C) was analyzed in 4-
week CCl4 treated control (Wt), Jnk2-/- and JnkΔhepa livers. (D) Representative Ki-67 
staining performed on frozen liver sections of the same livers. Scale bars: 100m. (E) 
Quantification of Ki-67 positive cells per view field is shown. (F) Protein levels of PCNA 
and CyclinD were determined by Western Blot in the same samples. GAPDH was used as 
a loading control. Data are expressed as mean±SEM (***p<0.001). Arrows denote positive 
cells. 
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Figure 5. Microarray analysis of JnkΔhepa livers and hepatocytes manifest 
dysregulation in cell proliferation, apoptosis and inflammation at basal levels. (A) 
Gene array analysis was performed in 8 week-old control (Wt) and JnkΔhepa liver and 
primary isolated hepatocytes. Correlation of the fold induction of genes in hepatocytes and 
liver is shown. Log2 expression values of the individual mice were divided by the mean of 
the sham-operated mice. Log ratios were saved in a txt file and analyzed with the Multiple 
Experiment Viewer. Top up- and down-regulated JNK-target substrates are shown (Red: 
Up-regulated; Blue: Down-regulated, n=3, -1.5<FC>1.5). (B) Ingenuity Pathway Analysis™ 
(IPA) was performed in the same samples and the expression values (in brackets) of the 
top up- and down-regulated genes in liver (left panel) and primary isolated hepatocytes 
(right panel) are represented. (C) Liver and hepatocytic protein extracts of untreated 
control (Wt), Jnk1Δhepa and JnkΔhepa were prepared. The protein expression levels of 
pStat3, c-myc and Bcl-XL were determined by Western Blot. GAPDH was used as loading 
control. (D) mRNA expression was determined in liver tissue and primary hepatocytes of 
untreated 8 week-old control (Wt), Jnk1Δhepa and JnkΔhepa mice. The mRNA expression 
levels of Saa2, Cmyc and BclXL are shown (n=3-5; *p<0.05; **p<0.01;***p<0.001). 
 
Figure 6. APAP modifies the morphology and exacerbates mitochondrial damage 
and necrotic cell death in primary JnkΔhepa hepatocytes. (A) Primary hepatocytes were 
isolated from control (Wt) and JnkΔhepa mice. A total number of 500.000 cells were seeded 
in 6-well plates and cultivated for up to 12h. Visible light microphotographs were taken in 
presence or absence of APAP and/or SP600125. Scale bars: 200m. (B) At the same time 
we performed Mitosox® staining to assess mitochondrial damage (red –arrows–, counter-
stained with DAPI, blue). Microphotographs were taken (scale bars: 100m).  (C) TUNEL 
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staining was performed. Scale bars: 200m. (D) TUNEL-positive cells were evaluated in 
the same mice and represented in percentage per view field. (E) The enzyme activity of 
Caspase3 was measured in frozen tissue. (F) Hepatocytic protein extracts were collected 
and treated with APAP for 8h in culture in presence or absence of APAP and/or 
SP600125. The protein expression levels of RIP3, RIP1, p65, pJNK, p-cJUN and pERK 
were determined by Western Blot. β-actin was used as a loading control.  
 
Figure 7. In vivo treatment with SP600125 suppresses APAP-induced liver injury in 
mice with combined JNK1 and JNK2 deletion in hepatocytes. (A) Serum AST (left) 
and ALT (right) levels were determined in control (Wt), Jnk1Δhepa and JnkΔhepa mice injected 
with SP600125 at the same time as APAP or pre-treated with SP600125, 2h before APAP 
challenge. Comparison with DMSO and APAP-treated mice is shown (n=10). (B+C) 
Representative H&E staining of liver sections collected from the same mice sacrificed 8h 
after treatment and examined by an experienced pathologist. Scale bars: 50 (upper 
panels) and 200m (lower panels), respectively. Dotted areas represent necrotic foci. (D) 
Liver extracts were collected and immunoblotting was performed, and the protein levels of 
PKC, pAMPK, AMPK and pJNK determined by Western Blot. (E) Phosphorylation of 
JunD was performed in hepatocytic extracts. GAPDH was used as loading control. (F) 
APAP triggers higher PKC, and lower AMPK – a survival pathway- expression inducing 
JNK phosphorylation and cell death. The JNK classical inhibitor SP600125 exerts an off-
target effect by facilitating phosphorylation of AMPK and preventing JNK phosphorylation 
in hepatocytes. 
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SUPPLEMENTARY MATERIAL AND METHODS 
Isolation and culture of primary hepatocytes  
Primary mouse hepatocytes were isolated from 7-8 week-old mice by collagenase 
perfusion. Living cells were plated on collagen-precoated petri dishes at a density of 
1.5 X 104/cm2 in DMEM medium (PAA Laboratories GmbH, Pasching, Austria) 
supplemented with L-glutamine, high glucose (4.5 g/l), 10% FBS and 100 U/ml 
penicillin/streptomycin. After 4 h incubation (37°C, 5% CO2) and every 2 days, 
medium was renewed. Hepatocytes were cultured up to 4 days. 
Quantitative real-time PCR (qPCR) 
Total RNA from liver tissues or cultured cells was isolated using Trizol reagent 
(Invitrogen, Karlsruhe, Germany). Due to low RNA amount in cultured cells, RNeasy 
Lipid Tissue Mini Kit was used to collect and purify RNA. Reverse-transcription was 
Supporting Document Click here to download Supporting Document Suppl. Info 161115.pdf 
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performed using an Omniscript RT Kit (Qiagen). Relative quantitative gene 
expression was measured via real-time PCR using a 7300 Real Time PCR System 
with SDS software 1.3.1 (Applied Biosystems, Foster City, CA) and a SYBR Green 
PCR Kit (Invitrogen, Carlsbad, CA). GAPDH expression was used as internal 
standard. Primer sequences can be provided upon request.  
Histological evaluation and immunofluorescence staining 
Hepatic tissue were fixed in 4% paraformaldehyde (PFA) immediately after 
extraction, embedded in paraffin, sectioned and stained for H&E or Sirius red. 
Samples were reviewed by a blinded pathologist who analyzed the degree of liver 
injury. The percentage of Sirius red area fraction in all animals was quantified on 10 
or 20 low-power (magnification, X10) fields per slide, using the NIH ImageJ® 
software (http://rsbweb.nih.gov/). Immunohistochemistry for CK-19 (DAKO, Hamburg, 
Germany), αSMA (Sigma, Steinheim, Germany), phospho-JNK (Cell Signaling, 
Danvers, MA) and F4/80 (Serotec, Dusseldorf, Germany) on paraffin sections, was 
performed using a Leica automatic stainer (Wetzlar, Germany). For the 
immunofluorescence staining, frozen cryosections were incubated with Ki-67 (Santa 
Cruz, Heidelberg, Germany), Collagen IA1 (Bio trend, Cologne, Germany) or in situ 
cell death detection kit (Roche, Mannheim, Germany) and incubated with 
fluorescence labelled secondary antibodies (AlexaFluor 488 and 564, Invitrogen, 
Carlsbad, CA, USA). All fluorescence-labelled cryosections were analyzed and 
documented using an Imager Z1 fluorescence microscope together with Axiovision 
software (Carl Zeiss, Jena, Germany).  
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Immunoblot analysis  
Liver tissues were homogenized in ice cold NP40-Buffer containing 50 mM Tri- HCl 
(pH 7.5), 150 mM NaCl, 0.5% NP-40 and 50 mM NaF freshly supplemented with 
Complete Mini (Roche), PhosSTOP (Roche), 1 mM orthovanadate and 1 mM 
pefablock. Protein concentrations were determined by BIO-RAD protein assay 
(BIORAD). Samples were separated by SDS-PAGE and transferred to a cellulose 
membrane and probed with antibodies for αSMA (Sigma), COLLAGEN 1AI 
(Monosan, Beutelsbach, Germany), PCNA (Dianova GmbH, Hamburg, Germany), 
CYCLIN A (Santa Cruz), CYCLIN D1, BCLXL and PKC (Santa Cruz), JNK1, JNK2, 
pJNK (pT183/Y185), P38, CMYC, STAT3, pAMPK, AMPK and MAPK/CDK 
Substrates (PXP*P or S*PXR/K) (34B2) (Cell Signaling), and GAPDH (Biorad, 
Munich, Germany). As secondary antibodies, anti-rabbit-HRP (Cell Signaling) and 
anti-mouse-HRP (Santa Cruz) were used.  
Microarray Analysis 
Liver and hepatocyte RNA using TRIzol reagent and purified with the RNeasy Mini Kit 
(Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions was 
isolated from 8-10 weeks-old male control Jnk2-/- and JnkΔhepa mice. Concentrations 
and purity of RNA samples were determined on a NanoDrop ND-1000 
spectrophotometer (Isogen, Maarssen, The Netherlands). RNA integrity was checked 
on an Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, The Netherlands) 
with 6000 Nano Chips. RNA samples from 3 mice per experimental group were used 
for microarray analysis. Samples were hybridized on Affymetrix GeneChip Mouse 
Genome 430 2.0 arrays in the microarray core laboratory of the Nutrigenomics 
Consortium at Wageningen University, The Netherlands. Hybridization, washing, and 
scanning of the arrays were performed according to standard Affymetrix protocols. 
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Array images were processed using packages from the Bioconductor project1. Probe 
sets were redefined according to Dai2. Probes were assigned to unique gene 
identifiers, in this case Entrez IDs. Arrays were normalized with the Robust Multi-
array Average (RMA) method. Differentially expressed probe sets were identified 
using intensity-based moderated paired t-statistics. P values were corrected for 
multiple testing using a false discovery rate (FDR) method. Detailed descriptions of 
the applied methods are available on request.   
Peptide lysis, dimethyl-labelling, phosphopeptide enrichment and LC-MS/MS analysis 
Primary hepatocytes were scraped off the cell culture dishes after APAP/DMSO 
treatment, washed three times in ice-cold PBS and lysed in 8M urea (in 50mM 
ammonium bicarbonate), containing protease and phosphatase inhibitor cocktails 
(Serva, Heidelberg, Germany) for 30 min on ice and cleared by centrifugation at 
20000 g, for 15 min at 4°C. After determination of protein concentration using a BCA 
assay (Thermo, Waltham, MA) the individual lysates (500 µg each) are reduced with 
DTT, alkylated with iodoacetamide, and proteolytically digested with the protease 
Lys-C (1:100, w/w) in 8M urea for 4h at 37°C. Samples were then diluted to 2M urea 
with 50 mM ammonium bicarbonate and further digested with trypsin (1:75, w/w) 
overnight at 37°C3, 4. The resulting peptide digests are desalted and dimethyl‐labelled 
“on column”5. Control (WT) mice derived peptides are labelled “light”, whereas 
JnkΔhepa mice derived peptides were labelled “heavy”. The labelled peptide digests 
are mixed in a 1:1 ratio, dried down and resuspended in 1 M glycolic acid in 80% 
ACN, 5% TFA). Phosphopeptide enrichment was performed using MagReSyn® Ti-
IMAC beads (ReSyn Biosciences, Gauteng, South Africa) according to the 
manufacturer’s instructions. Samples were then analysed on a nanoLC-MS/MS 
System (LC: Ultimate 3000 (Dionex, Dreieich, Germany); MS: Orbitrap Elite 
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(Thermo)). The raw data obtained from the mass spectrometer were processed and 
quantified with MaxQuant (version 1.4.1.2). The relevant MS and MS/MS spectra 
were searched against a forward‐decoy Swissprot Homo sapiens database (version 
09/2014). 
 
Transplantation of bone marrow-derived cells 
We transferred bone marrow from JnkΔhepa and control (WT) mice into 6 week-old 
JnkΔhepa and control isogeneic recipients (n=6-7 mice per group) after ablative γ-
irradiation, as described previously6. Two months after BMT mice were subjected to 
either 4 weeks treatment with CCl4 (0.6 mL/kg body weight, diluted in corn oil, 
injected intraperitoneally every 3 days) or BDL. At this time, mice were sacrificed and 
samples collected. 
Serum parameters 
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and 
alkaline phosphatase (AP) activity (UV test at 37°C) were measured in the Central 
Laboratory Facility at University Hospital RWTH Aachen according to standard 
procedures. 
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SUPPLEMENTARY TABLES AND FIGURES 
Supplementary Table I. Origin and clinical features of liver samples from patients 
with DILI. (f: female; m: male; Bili: total bilirrubin; GLDH: glutamate dehydrogenase; 
TPT: prothrombin time; INR: international normalized ratio; αPTT: activated partial 
thromboplastin time; NSAID: non-steroidal anti-inflammatory drug). 
Supplementary Figure 1. (A) Activation of pJNK in liver samples of patient samples 
of normal liver human tissue (C3, C4). (B+C) PCR blots of tail DNA from Wt and 
Jnk1Δhepa (upper panel) and control (Wt), Jnk2-/-, and JnkΔhepa (lower panel) mice 
confirmed the respective phenotype of interest.  
Supplementary Figure 2. (A+B) A basal study of untreated female (♀) and male (♂) 
8-week-old control (Wt) or JnkΔhepa mice was performed. Representative macroscopic 
view of livers (scale bars: 10mm) and H&E staining of liver sections (scale bars 
100m) from each mice group is shown. (C+D) Serum AST and ALT was 
represented in a graph. (E+F) Liver weight (LW) and body weight of these mice is 
shown, and the liver versus body weight ratio (%LW/BW) calculated.  
Supplementary Figure 3. (A) Control (Wt), Jnk1Δhepa and JnkΔhepa mice were 
injected with APAP for 8h and sacrificed. The liver versus body weight ratio 
(%LW/BW) was then calculated. (B) Isoprostanes, indicators of lipid peroxides were 
measured in livers of 8h APAP-treated control (Wt) and JnkΔhepa mice, and 
represented as pg/ml. (C) Densitometry analysis of the protein expression levels of 
P38 was performed in these mice and represented as arbitrary units of fluorescence 
(AUF).  
Supplementary Figure 4. (A) Control (Wt) or JnkΔhepa mice were injected with GalN 
and 30 min later with LPS. 8h thereafter mice were sacrificed. (B) Survival curve of 
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control (Wt) or JnkΔhepa mice treated with GalN+LPS and sacrificed 8h later. (C) 
Serum levels of AST, ALT and GLDH were determined after GalN+LPS-treated 
control (Wt) or JnkΔhepa mice. (D) Macroscopic (upper panel; Scale bars: 10mm) and 
microscopic (lower panel; Scale bars: 100m) appearance of control (Wt) or JnkΔhepa 
mice after 8h GalN+LPS treatment (E) The percentage of liver vs body weight ratio 
was calculated and represented in a graph.  
Supplementary Figure 5. (A) Representative macroscopic view of control (Wt), 
Jnk2-/- and JnkΔhepa livers, 28 days after repeated injections of CCl4. Corn-oil 
injections were used as controls. (B) Representative Sirius red staining of paraffin 
sections from the same livers. (C+D) Quantification of Sirius red and CollagenIA1 
stainings were performed using Image J© Software and represented as percentage of 
area fraction. (E) Densitometry analysis of the protein expression levels of SMA 
was performed in these mice and represented as arbitrary units of fluorescence 
(AUF). (F) mRNA levels of Timp1 and Mmp2 were determined by qRT-PCR in liver 
tissues of (n=5-10). Data are expressed as mean±SEM (*p<0.05; **p<0.01; 
***p<0.001). 
Supplementary Figure 6. Control (Wt), Jnk2-/- and JnkΔhepa livers were subjected for 
4 weeks of repeated CCl4 injections. (A) mRNA levels of Pcna were determined by 
qRT-PCR in liver tissues (n=6-8; **p<0.01). (B) Densitometry analysis of the protein 
expression levels of PCNA and CyclinD was performed in these mice and 
represented as arbitrary units of fluorescence (AUF). 
Supplementary Figure 7. The inflammatory profile is increased in absence of JNK in 
hepatocytes.  (A) Representative CD11b staining performed on frozen liver sections 
of control (Wt), Jnk2-/- and JnkΔhepa livers after 4 weeks of repeated CCl4 injections. 
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Scale bars: 100m. Quantification of positive cells was performed in 7-10 view-fields. 
(B) Representative F4/80 staining performed on frozen liver sections of the same 
livers. Scale bars: 100m. Quantification of F4/80 positive cells per view field is 
shown. mRNA levels of IL1α (C), IL1β (D), Mcp1 (E) and Tnf (F) were determined 
by qRT-PCR in liver tissue (n=6-8). Data are expressed as mean±SEM (*p<0.05; 
**p<0.01; ***p<0.001). 
Supplementary Figure 8. Venny diagram shows comparative gene expression 
overlap in untreated 8 week-old control (Wt) and JnkΔhepa livers and primary 
hepatocytes. (A) Up-regulated genes. (B) Down-regulated genes. (C+D) Validation of 
gene array analysis by mRNA expression was performed in liver tissue and primary 
hepatocytes of 8 week-old untreated control (Wt), Jnk1Δhepa and JnkΔhepa mice. The 
mRNA expression levels Bad and Jnk2 are shown (*p<0.05; **p<0.01;***p<0.001). 
Supplementary Figure 9. (A) Primary hepatocytes were isolated from control (Wt), 
Jnk2-/- and JnkΔhepa mice. A total number of 500.000 cells were seeded in 6-well 
plates and cultivated for up to 48h. Visible light microphotographs were taken in 
untreated hepatocytes. Scale bars: 100m. (B) Representative TUNEL stainings of 
primary hepatocytes. Dead cells are stained green; total cells were counter-stained 
with DAPI (blue). Scale bars: 100m. (C) Staining for BrdU was performed in 
coverslips and counterstained to DAPI (blue). Scale bars: 100m. (D) BrdU-positive 
cells were counted in untreated control (Wt) and JnkΔhepa hepatocytes, and displayed 
in a graph.  
Supplementary Figure 10. Primary hepatocytes were isolated from control (Wt) and 
JnkΔhepa mice. A total number of 500.000 cells were seeded in 6-well plates and 
cultivated for up to 12h. (A) Reactive oxygen species (ROS) were measured in 
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presence or absence of APAP and/or SP600125, an inhibitor of the JNK pathway. (B) 
Annexin V (green)/Ethidium Homodimer III (red)/DAPI (blue) was performed and 
microphotographs were taken. (C) Quantification of the double Annexin V/Ethidium 
Homodimer III/ DAPI-positive cells was graphed. Values are mean±SEM from at least 
6 mice per group (*p<0.05; **p<0.01). 
Supplementary Figure 11. (A) Hepatocytic protein extracts from 8h-APAP-treated 
control (Wt) and JnkΔhepa primary hepatocytes were labelled with beads, digested with 
trypsin, and the phosphopeptides were enriched, and analyzed using mass 
spectrometry. (B) The expression of phosphoMAPK/CDK substrates was assessed in 
untreated and 8h-APAP-treated control (WT) and JnkΔhepa primary hepatocytes. 
Potential target proteins of JNK with matching molecular weights are displayed on the 
right. Values are mean±SEM from at least 6 mice per group (**p<0.01 and 
***p<0.001). 
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Origin and clinical features of liver samples from patients with DILI. (f: female; m: male; Bili: total bilirrubin;
GLDH: glutamate dehydrogenase; TPT: prothrombin time; INR: international normalized ratio; αPTT:
activated partial thromboplastin time; NSAID: non-steroidal anti-inflammatory drug).
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